Veterinary Apothecary highlights new dermatology drug, safety signals: full analysis
Version 2 — Full analysis
A new edition of dvm360’s Veterinary Apothecary pulls together several threads shaping companion animal medicine right now: new drug approvals, vaccine-related safety questions, oncology and antimicrobial resistance research, compounding oversight, and specialist commentary intended to help clinicians make sense of a fast-moving therapeutic landscape. The most consequential item for many small animal teams is the arrival of Zenrelia (ilunocitinib), an FDA-approved oral JAK inhibitor for dogs with allergic dermatitis and atopic dermatitis. FDA approved the drug on September 19, 2024, for dogs at least 12 months of age. (animaldrugsatfda.fda.gov)
That approval came with unusual visibility because the label includes a boxed warning around vaccination. In the FDA Freedom of Information summary, the agency described study findings showing immunosuppression-related concerns in dogs receiving Zenrelia concurrently with vaccines, including fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to some vaccines. Based on those findings, FDA said Zenrelia should be stopped at least 28 days to 3 months before vaccination and withheld for at least 28 days after vaccination. (animaldrugsatfda.fda.gov)
The regulatory scrutiny didn’t stop at approval. On January 28, 2025, FDA sent Elanco a warning letter saying promotional materials for Zenrelia made false or misleading claims about the drug’s safety and effectiveness. The agency specifically cited concern that marketing created a misleading impression despite the product’s boxed warning and additional precautions around infections, hematologic changes, and new neoplastic conditions observed during studies. That sequence matters because it shows how quickly post-approval messaging around a high-interest dermatology product can become a regulatory issue. (fda.gov)
The broader dermatology market is also getting more crowded. Outside the U.S., MSD Animal Health reported 2025 congress data on atinvicitinib, marketed as NUMELVI in Europe, describing it as a second-generation JAK1-selective inhibitor for canine atopic dermatitis and allergic dermatitis. In one company-reported trial, 87.5% of dogs at the recommended dose achieved at least a 50% reduction in itching or lesion severity versus 23.1% with placebo over 28 days. That’s company-sponsored evidence rather than U.S. regulatory labeling, but it signals how competitive the canine dermatology pipeline has become. (msd-animal-health.com)
Specialist commentary adds useful context here. In recent dvm360 interviews, dermatologist Christina Gentry, DVM, DACVD, emphasized that dermatology is “ever changing” and that general practitioners are regularly having to adapt to new drugs and updated treatment thinking. That framing fits this moment: clinicians aren’t just choosing among itch therapies, they’re managing a growing set of tradeoffs involving immune effects, secondary infections, comorbidities, cost, and monitoring. (dvm360.com)
The roundup’s value is that it does not stop with one product. It also reflects a profession trying to absorb parallel changes in oncology, infectious disease, diagnostics, and medication access. On the oncology side, independent specialty capacity continues to expand, with Heal Cancer Care for Pets opening in Seattle as a dogs-and-cats-only oncology practice. In diagnostics, MiDOG Animal Diagnostics announced an enhanced whole-genome sequencing service that can identify bacteria, fungi, and parasites to the species level while also detecting antimicrobial resistance genes and virulence factors from a single sample, with results in two days. Those kinds of tools matter because they push prescribing decisions closer to organism-level and resistance-aware treatment selection rather than empiric therapy alone.
That antimicrobial resistance thread is showing up elsewhere too. dvm360 recently highlighted Paul Plummer, DVM, PhD, dean of the University of Tennessee College of Veterinary Medicine, for his election to the American Academy of Microbiology’s 2026 class of fellows. Plummer also chairs the Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria and leads the National Institute of Antimicrobial Resistance Research and Education. For clinicians, that recognition is more than a personnel note; it is a reminder that antimicrobial stewardship remains a central scientific and public-health issue running alongside newer therapeutics and diagnostics.
Another underappreciated piece of the current prescribing environment is compounding. In separate dvm360 coverage, the publication reviewed how compounded medications fit into modern veterinary practice, emphasizing that compounding is patient-specific customization rather than a substitute for FDA-approved products, and that it operates under tighter regulatory expectations than many teams may realize. The article points to updated USP standards and FDA Guidance for Industry #256 as part of a more demanding compliance landscape. That matters in the same operational sense as Zenrelia’s vaccine warning: practices increasingly need systems that connect prescribing decisions with documentation, client communication, and liability awareness.
The same is true at the business and workflow level. Outside the roundup, Veterinary Management Groups and the American Animal Hospital Association released an updated veterinary chart of accounts intended to modernize financial reporting and improve benchmarking, reflecting changes in services, revenue streams, and practice operations. Instinct Science also released new survey findings on general practice and specialty/ER settings that highlighted shifts in workload, staffing models, pressure points, and technology adoption. Those updates may seem separate from therapeutics, but they help explain why implementing a drug with vaccine washout requirements or more intensive monitoring can be harder in real clinics than it looks on paper.
Education and early research are moving in parallel. Recent dvm360 and Vet Candy coverage pointed to a growing stream of clinically relevant work from veterinary training programs and residencies, including UC Davis resident and fellow research on kitten blood typing, fungal diagnostics in dogs, and neurofilament light as a biomarker for canine degenerative myelopathy. None of that changes Zenrelia’s label, but it does reinforce the same broader point: the pipeline of veterinary medicine now includes not just new products, but new diagnostics, biomarkers, and care models that can change how cases are worked up and followed over time.
Why it matters: For veterinary professionals, this roundup reflects a wider shift in companion animal medicine toward more targeted therapies with more operational complexity. A new dermatitis drug may improve options for refractory or difficult cases, but it also creates new demands on the care team: checking vaccine history before prescribing, coordinating future boosters, documenting washout periods, screening for infection risk, and setting realistic expectations with pet parents. In practical terms, the drug choice now has downstream effects on preventive care timing, technician workflows, and client adherence. (animaldrugsatfda.fda.gov)
It also underscores the value of reading beyond headlines and into primary regulatory documents. FDA notes that FOI summaries are intended to show the evidence the agency relied on for approval decisions. For busy clinicians, those summaries can be one of the clearest ways to understand what changed, what the real safety signals were, and how label language should shape day-to-day use. In a period when roundups increasingly mix product news, early research, commentary, and practice-management developments, that distinction is worth keeping front of mind. The same goes for adjacent issues such as compounding rules, resistance diagnostics, and benchmarking tools: each can influence care quality, but not all carry the same evidentiary or regulatory weight. (fda.gov)
What to watch: Expect continued attention on post-market experience with Zenrelia, further competition from newer antipruritic agents, and more discussion about how dermatology protocols should be adapted so vaccine timing, safety monitoring, and pet parent communication stay aligned. Also watch for wider uptake of resistance-focused diagnostics, continued emphasis on antimicrobial stewardship leadership, and more pressure on clinics to translate new therapies into workable systems for scheduling, documentation, and benchmarking. (animaldrugsatfda.fda.gov)